German regulator grants reimbursement status to Morphic Medical’s obesity device

Germany's Federal Joint Committee (G-BA) has granted reimbursement status to Morphic Medical's obesity treatment device in Berlin on May 15, 2023, marking a significant milestone in the fight against obesity-related healthcare costs. This decision means that German public health insurance will now cover the innovative device, potentially improving access for thousands of patients struggling with obesity. The reimbursement approval follows extensive clinical trials that demonstrated the device's effectiveness in helping patients achieve sustainable weight loss without invasive surgical procedures. Morphic Medical, a medical technology company specializing in metabolic disorders, has positioned this device as a less invasive alternative to traditional bariatric surgeries, offering new hope for patients who have not responded to conventional weight management approaches. The economic implications of this decision are substantial, as obesity-related healthcare costs in Germany exceed €30 billion annually, with the reimbursement status expected to reduce long-term expenses while improving patient outcomes.